QC
ALGS icon

Quadrature Capital’s Aligos Therapeutics ALGS Stock Holding History

Quadrature Capital’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.4K Buy
+10,822
New +$82.1K ﹤0.01% 1251

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Quadrature Capital's ALGS Position: Q1 2026 in Review

Quadrature Capital opened a new position in Aligos Therapeutics (ALGS) in Q1 2026: 10,822 shares worth $80.4K. The stake represents ﹤0.01% of the portfolio and ranks #1251 among its holdings.

35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Quadrature Capital held 10,822 shares of Aligos Therapeutics worth $80.4K as of Q1 2026.
  • Aligos Therapeutics was a new Quadrature Capital position in Q1 2026.
  • Aligos Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1251 holding.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.